iPSC-Derived Cardiomyocyte Therapy for Heart Failure from Japan
Induced pluripotent stem cell (iPSC)-derived cardiomyocytes for intramyocardial injection to repair damaged heart tissue post-myocardial infarction. These engineered cell cultures are cell therapy products under HTS 3002.51.00.00, modified biotechnologically for cardiac regeneration. They integrate and beat synchronously with host tissue.
Duty Rate — Japan → United States
0%
Rate breakdown
9903.05.860%Universal product exemption (U.S. note 52(b))
Import Tips
• Submit genetic stability and pluripotency marker test results for customs clearance
• Transport in vapor-phase liquid nitrogen to prevent differentiation